Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;37(5):885-894.
doi: 10.3904/kjim.2022.138. Epub 2022 Jul 29.

Inflammatory bowel disease in Korea: epidemiology and pathophysiology

Affiliations
Review

Inflammatory bowel disease in Korea: epidemiology and pathophysiology

Jung Won Lee et al. Korean J Intern Med. 2022 Sep.

Abstract

Inflammatory bowel disease (IBD) refers to a group of disorders, including Crohn's disease and ulcerative colitis, that exhibit similar but distinct manifestations. These diseases are characterized by refractory and chronic inflammation of the bowel. IBD is usually accompanied by severe symptoms. When a patient presents with suspected IBD, physicians encounter various challenges in terms of diagnosis and treatment. In addition, given such characteristics, the associated medical expenses gradually increase. Although IBD was formerly known as a disease of Western countries, the incidence and prevalence are increasing in Korea. Korean investigators have accumulated a great deal of knowledge about the regional characteristics and epidemiology of the disease, especially via well-organized, joint cohort studies. Against this background, this article describes the epidemiology of IBD in Korea compared to that in the West. In addition, an overview of the pathophysiology of the disease is provided, focusing on the latest results.

Keywords: Epidemiology; Inflammatory bowel diseases; Korea; Pathophysiology.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

References

    1. Im JP, Ye BD, Kim YS, Kim JS. Changing treatment paradigms for the management of inflammatory bowel disease. Korean J Intern Med. 2018;33:28–35. - PMC - PubMed
    1. Lee HS, Park SK, Park DI. Novel treatments for inflammatory bowel disease. Korean J Intern Med. 2018;33:20–27. - PMC - PubMed
    1. Lee J, Im JP, Han K, et al. Changes in direct healthcare costs before and after the diagnosis of inflammatory bowel disease: a nationwide population-based study. Gut Liver. 2020;14:89–99. - PMC - PubMed
    1. Kim JW, Lee CK, Rhee SY, Oh CH, Shim JJ, Kim HJ. Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: a nationwide population-based study. J Gastroenterol Hepatol. 2018;33:847–854. - PubMed
    1. Yen HH, Weng MT, Tung CC, et al. Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population based study. Intest Res. 2019;17:54–62. - PMC - PubMed

MeSH terms